Savior Lifetec

Savior Lifetec EBIT per Employee

The EBIT per Employee of Savior Lifetec (4167.TWO) as of Oct 26, 2026 is 516,257.81 TWD. In the previous year, EBIT per Employee was 309,635.42 TWD — a change of 66.73% (higher).

EBIT per Employee

516,257.81TWD

YoY

66.73%

Last updated:

EBIT per Employee of Savior Lifetec is 2025 516,257.81 TWD. EBIT per Employee of Savior Lifetec was 2024 309,635.42 TWD. It decreases by 66.73% higher compared to the previous year.

The Savior Lifetec EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-912,171.88 TWD
Jan 1, 2019
89,007.81 TWD
Jan 1, 2020
747,520.83 TWD
Jan 1, 2021
71,148.44 TWD
Jan 1, 2022
135,427.08 TWD
Jan 1, 2023
-6,302.08 TWD
Jan 1, 2024
309,635.42 TWD
Jan 1, 2025
516,257.81 TWD
The Savior Lifetec EBIT per Employee history
YEAREBIT per EmployeeYoY
516,257.81TWD+66.73%
309,635.42TWD-5,013.22%
-6,302.08TWD-104.65%
135,427.08TWD+90.34%
71,148.44TWD-90.48%
747,520.83TWD+739.84%
89,007.81TWD-109.76%
-912,171.88TWD-812.37%
128,046.88TWD-128.62%
-447,325.52TWD-62.93%
-1.21 MTWD+39.23%
-866,622.40TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

EBIT per Employee of Savior Lifetec is 516,257.81 TWD in 2025.

EBIT per Employee of Savior Lifetec changed from 309,635.42 TWD to 516,257.81 TWD, representing a 66.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Savior Lifetec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Savior Lifetec

All Key Metrics — Savior Lifetec